Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM6B | O15054 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KDM4A | O75164 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30465506 | 1.00 | KDM4C (0.49) | KDM4CALDH1A1KDM4ETDP1MAPT | |
| SCHEMBL3464020 | 0.98 | KDM4C (0.47) | KDM4CALDH1A1KDM4ETDP1MAPT | |
| Hydrochloric Acid SCHEMBL11590758 | 0.98 | KDM4C (0.47) | KDM4CALDH1A1KDM4ETDP1MAPT | |
| SCHEMBL115719 | 0.85 | KDM4C (0.53) | KDM4CALDH1A1KDM4ETDP1MAPT | |
| SCHEMBL30578227 | 0.85 | KDM4C (0.53) | KDM4CALDH1A1KDM4ETDP1MAPT | |
| SCHEMBL334854 | 0.85 | CA12 (0.47) | ALDH1A1KDM4ETDP1MAPTKMT2A | |
| SCHEMBL9646602 | 0.83 | KDM4E (0.59) | ALDH1A1KDM4EMAPTKMT2AL3MBTL1 | |
| SCHEMBL11590754 | 0.83 | CA12 (0.46) | KDM4CALDH1A1KDM4ETDP1MAPT | |
| Hydrochloric Acid SCHEMBL459608 | 0.83 | KDM4C (0.52) | KDM4CALDH1A1KDM4ETDP1MAPT | |
| SCHEMBL3966553 | 0.83 | SIRT3 (0.59) | ALDH1A1KDM4ETDP1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | claimed |
| CN-106986789-A | Hydroquinone compound and preparation method thereof and the application in antitumor or immunological regulation | 中国人民解放军军事医学科学院生物医学分析中心 | 2017-07-28 | — | — | CN | claimed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4727943-A1 | INHIBITORS OF MET KINASE | Celyn Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12595245-B2 | Inhibitors of MET kinase | CELYN THERAPEUTICS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY INC (US) | 2026-02-26 | — | — | US | disclosed |
| WO-2025235833-A1 | RXFP1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-118955471-B | Polysubstituted piperazine compound with double chiral centers, and preparation method and application thereof | 河源市深河人民医院(暨南大学附属第五医院) | 2025-04-18 | — | — | CN | disclosed |
| CN-119707919-A | Deuterated piperazine compound and preparation method and application thereof | 山东大学 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024259060-A1 | INHIBITORS OF MET KINASE | KINNATE BIOPHARMA INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20040122014-A1 | Muscarinic M2 receptor antagonists; such as 4-{N-[7-(3-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine; reduced blurred vision, constipation and dry mouth side effects | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004041806-A2 | SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040058937-A1 | Heterocyclic mutilin esters and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1309565-A1 | HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-05-14 | — | — | EP | disclosed |
| US-20020103392-A1 | CORTICOID-17,21-DICARBOXYLIC ESTERS AND CORTICOSTEROID 17-CARBOXYLIC ESTER 21-CARBONIC ESTERS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-01 | — | — | US | disclosed |
| WO-2002012199-A1 | HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-14 | — | — | WO | disclosed |
| US-5608093-A | ANTIINFLAMMATORY AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-03-04 | — | — | US | disclosed |
| EP-0640616-A2 | 17-Alkylcarbonate, 21-0-carbonic/carboxylic acid esters of corticosteroids, a method for their production and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-03-01 | — | — | EP | disclosed |
| EP-0306251-A2 | Azolidinedione derivatives | PFIZER INC. (US) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122014-A1 | Muscarinic M2 receptor antagonists; such as 4-{N-[7-(3-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine; reduced blurred vision, constipation and dry mouth side effects | CHRM2, CHRM1, CHRM3 | KDM4C 1973/4885ALDH1A1 1429/4885KDM4E 2117/4885 |
| US-20040058937-A1 | Heterocyclic mutilin esters and their use as antibacterials | MLN, MSH2, MRPL21 | KDM4C 4721/4885ALDH1A1 852/4885KDM4E 4142/4885 |
| US-12595245-B2 | Inhibitors of MET kinase | MET, ABL1, ERBB2 | KDM4C 721/4885ALDH1A1 2585/4885KDM4E 393/4885 |
| US-20020103392-A1 | CORTICOID-17,21-DICARBOXYLIC ESTERS AND CORTICOSTEROID 17-CARBOXYLIC ESTER 21-CARBONIC ESTERS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | NR3C1, HSD3B1, HSD17B7 | KDM4C 1319/4885ALDH1A1 1867/4885KDM4E 2072/4885 |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | KDM4C 922/4885ALDH1A1 1094/4885KDM4E 1719/4885 |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | KDM4C 794/4885ALDH1A1 1500/4885KDM4E 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.